RET and lung carcinoma: MET mutations in lung cancer are considered to be predictors of susceptibility to the MET inhibitor crizotinib, whereas RET translocations are correlated with a positive response to targeted therapy with RET inhibitors such as cabozatinib, vandetinib, and alectinib [10].